Unpacking the Real-world Results From the AD-VISE Study With Dr. Melinda Gooderham September 17, 2025
AD Pipeline Watch: Rocatinlimab, an Anti-OX40 Monoclonal Antibody, Shows Sustained Safety, Efficacy September 9, 2025
Amlitelimab, Sanofi’s Anti-OX40L Antibody, Hits All Primary and Key Secondary Endpoints in Phase 3 AD Trial September 4, 2025
